Tetanus Toxoid is a sterile suspension of formaldehyde-inactivated tetanus toxin (tetanospasmin) derived from Clostridium tetani. It is a vaccine used for active immunization against tetanus, a life-threatening neurological disease caused by the potent exotoxin. In the Indian context, it is a critical component of the Universal Immunization Programme (UIP) and is widely used for both primary immunization and booster doses. It is available as a monovalent vaccine or in combination with diphtheria toxoid (Td, DT) and pertussis vaccine (DTP, DTaP).
Adult: Primary Immunization (unvaccinated): 0.5 mL IM, 3 doses: 2nd dose 4-8 weeks after 1st, 3rd dose 6-12 months after 2nd. Booster: 0.5 mL IM every 10 years or as per wound prophylaxis.
Note: For intramuscular (IM) use only. Preferred site: anterolateral thigh in infants, deltoid in older children and adults. Do not inject intravenously, intradermally, or subcutaneously (unless specific contraindication to IM). Shake vial/ampoule well before withdrawal. Use a separate sterile syringe and needle for each individual.
Tetanus Toxoid is a formaldehyde-detoxified toxin that retains its immunogenicity but not its toxicity. Upon intramuscular administration, it is taken up by antigen-presenting cells, processed, and presented to helper T-cells. This stimulates a T-cell-dependent B-cell response, leading to the production of neutralizing antibodies (primarily IgG) against tetanus toxin. These antibodies prevent the binding of the actual tetanus toxin to neuronal receptors, thereby preventing the onset of disease.
Pregnancy: Category A (Indian classification). Tetanus Toxoid (as Td) is SAFE and HIGHLY RECOMMENDED in pregnancy. It prevents maternal and neonatal tetanus. The WHO and MoHFW, India recommend at least 2 doses during pregnancy, spaced at least 4 weeks apart, with the 2nd dose given at least 2 weeks before delivery.
Driving: No effect. However, syncope can occur shortly after vaccination; observe for 15 minutes post-administration.
| Immunosuppressants (e.g., high-dose corticosteroids, chemotherapy, biologics) | Diminished or suboptimal immune response to the vaccine. | Major |
| Anticoagulants (e.g., Warfarin) | Increased risk of hematoma at injection site. Use fine needle and apply prolonged pressure. | Moderate |
| Other Vaccines (Inactivated) | Can generally be administered simultaneously at different sites without interference. No interaction with tetanus toxoid efficacy. | Minor |
Same composition (Tetanus Toxoid (NA)), different brands: